We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

US FDA draft guideline seeks to foster drug development for chronic fatigue syndrome

News

Executive Summary

The US Food and Drug Administration has released a draft guidance to help drug sponsors develop treatments for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), a condition for which there are currently no FDA-approved medicines1,2.